Drug Trial Radar · NCT00286481
Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: May 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,362
Actual
Start
Mar 2006
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.
Conditions
- Hypercholesterolemia
Interventions
Lapaquistat acetate and simvastatinDrug
Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Lapaquistat acetate and simvastatinDrug
Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
SimvastatinDrug
Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Low Density Lipoprotein cholesterolTime frame: Week 12 or Final Visit
Locations
67 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Chandler, Arizona
Site not named
Scottsdale, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Tucson, Arizona
Site not named
Beverly Hills, California
Site not named
Long Beach, California
Site not named
Sacramento, California
Site not named
Spring Valley, California
Site not named
Colorado Springs, Colorado
Site not named
Hialeah, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Kissimmee, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Pembroke Pines, Florida
Site not named
Pinellas Park, Florida
Site not named
Stuart, Florida
Site not named
West Palm Beach, Florida
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Peoria, Illinois
Site not named
Indianapolis, Indiana
Site not named
Overland Park, Kansas
Site not named
Wichita, Kansas
Site not named
Louisville, Kentucky
Site not named
Edina, Minnesota
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
Margate City, New Jersey
Site not named
Raleigh, North Carolina
Site not named
Statesville, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Kettering, Ohio
Site not named
Bartlesville, Oklahoma
Site not named
Portland, Oregon
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.